Thailand Issues Deadline For Drug Price Slashes Or Compulsory Licenses (Thailand)
This article was originally published in PharmAsia News
Executive Summary
Thailand's chief negotiator in price talks with foreign pharmaceuticals says Novartis and Sanofi-Aventis have until the end of this month to lower the costs for two drugs by more than 60 percent or face compulsory licenses. Dr. Siriwat Tiptaradol, chairman of the negotiating committee for compulsory licensing of patented drugs, said Sanofi-Aventis offered to trim its price by only 10 percent for Taxotere (docetaxel) for treating lung and breast cancer. Roche's OSI Pharms unit was expected to make a proposal for its Tarceva (erlotinib) before the end of December. Siriwat said Sanofi and Novartis, whose Femara (letrozole) is included in the 60 percent demand, have until the end of the month to respond to the demand or he will end negotiations and report to the Public Health minister, who will then consider compulsory licensing. Siriwat said a Novartis proposal to distribute its Gleevec (imatinib mesylate) leukemia drug for free to registered cancer patients was satisfactory. (Click here for more
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.